A pill vs. a shot: which eases Kidney-Related anemia better?

NCT ID NCT07755683

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial asks whether an oral medication called daprodustat can match the effectiveness of the injectable drug epoetin alpha in treating anemia linked to chronic kidney disease. Adults with stage 3-5 kidney disease who are not on dialysis and have low hemoglobin levels will receive either daprodustat pills or epoetin alpha injections for one month. Researchers will compare changes in hemoglobin and ferritin levels to see if the pill offers a viable, more convenient alternative to injections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
daprodustat (an oral medication) and epoetin alpha (an injectable medication)
What this could lead to
If daprodustat works as well as epoetin alpha, it could offer a convenient pill alternative to injections for managing anemia in chronic kidney disease.
What could go wrong
This is a small, short-term study (60 people, one month) that only measures blood markers, not long-term outcomes. Results may not apply to everyone, and daprodustat may have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Services Hospital Lahore Pakistan

    Lahore, Punjab Province, 54000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.